In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Hold rating on Xenetic Biosciences (XBIO – Research Report). The company’s shares opened today at $2.93.
Pantginis covers the Healthcare sector, focusing on stocks such as PDS Biotechnology, Clene, and Ligand Pharma. According to TipRanks, Pantginis has an average return of -14.2% and a 26.14% success rate on recommended stocks.
The analyst consensus on Xenetic Biosciences is currently a Hold rating.
See the top stocks recommended by analysts >>
The company has a one-year high of $7.51 and a one-year low of $2.40. Currently, Xenetic Biosciences has an average volume of 8,523.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Xenetic Biosciences (XBIO) Company Description:
Xenetic Biosciences, Inc. is a biopharmaceutical company, which focuses on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. The XCART has the potential to fuel a robust pipeline of therapeutic assets targeting oncology indications. Additionally, Xenetic is leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. The PolyXen has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. Xenetic Biosciences was founded on and is headquartered in Framingham, MA.
Read More on XBIO:
